ILMN Illumina Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ILMN

Price (delayed)

$192.64

Market cap

$29.09B

P/E Ratio

35.67

Dividend/share

N/A

EPS

$5.4

Enterprise value

$30.49B

?
Relative Growth: Rel. Growth: 28
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 26
Relative Profitability: Rel. Profitability: 79

The Illumina Billion Cell Atlas — the world's largest genome-wide genetic perturbation dataset — is capturing how one billion individual cells respond to genetic changes via CRISPR across more than ...

Highlights
The equity has increased by 26% YoY and by 6% from the previous quarter
Illumina's revenue has increased by 4.9% YoY and by 2.3% QoQ
The stock's price to earnings (P/E) is 44% more than its last 4 quarters average of 24.8
ILMN's net income is down by 34% year-on-year and by 3.3% since the previous quarter
Sector: Healthcare
Industry: Diagnostics & Research
Website: http://www.illumina.com
Peers: PACB A TMO DHR

Key stats

What are the main financial stats of ILMN

ILMN stock price

How has the Illumina stock price performed over time
Intraday
-0.14%
1 week
-0.56%
1 month
1.36%
1 year
90.53%
YTD
46.87%
QTD
9.56%

Financial performance

How have Illumina's revenue and profit performed over time
Revenue
$4.49B
Gross profit
$2.98B
Operating income
$882M
Net income
$825M
Gross margin
66.4%
Net margin
18.4%
Illumina's net margin has decreased by 37% YoY and by 5% QoQ
Illumina's operating margin has decreased by 35% YoY
ILMN's net income is down by 34% year-on-year and by 3.3% since the previous quarter
The operating income has decreased by 32% YoY but it has increased by 3.6% from the previous quarter

Price vs fundamentals

How does ILMN's price correlate with its fundamentals

Growth

What is Illumina's growth rate over time

Valuation

What is Illumina stock price valuation
ILMN P/E details
P/E
35.67
P/B
10.27
P/S
6.47
EV/EBIT
27.4
EV/EBITDA
22.02
EV/Sales
6.79
The stock's price to earnings (P/E) is 44% more than its last 4 quarters average of 24.8
Illumina's EPS has decreased by 32% YoY and by 2.2% QoQ
The price to book (P/B) is 68% higher than the 5-year quarterly average of 6.1 and 39% higher than the last 4 quarters average of 7.4
The equity has increased by 26% YoY and by 6% from the previous quarter
ILMN's P/S is 44% above its last 4 quarters average of 4.5 and 2.7% above its 5-year quarterly average of 6.3
Illumina's revenue has increased by 4.9% YoY and by 2.3% QoQ

Efficiency

How efficient is Illumina business performance
The ROE has contracted by 44% YoY and by 9% from the previous quarter
The company's return on assets fell by 38% YoY and by 5% QoQ
Illumina's return on sales has decreased by 30% YoY and by 6% QoQ
ILMN's return on invested capital is down by 21% year-on-year and by 3.6% since the previous quarter

Dividends

What is ILMN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ILMN.

Financial health

How did Illumina financials performed over time
The total assets is 74% more than the total liabilities
The total assets has grown by 9% YoY
The quick ratio has contracted by 3.9% YoY
Illumina's debt is 14% lower than its equity
The equity has increased by 26% YoY and by 6% from the previous quarter
The debt to equity is down by 23% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.